Description
Table of Contents
Section I: Best practices and considerations when designing a new project 1. iPSC culture: best practices from sample procurement to reprogramming and differentiation 2. Phenotypic assay development with iPSC-derived neurons: technical 3. Derivation of cortical interneurons from human pluripotent stem cells to model neurodevelopmental disorders 4. Development of transcription factor-based strategies for neuronal differentiation from pluripotent stem cells 5. Differentiation of Purkinje cells from pluripotent stem cells for disease phenotyping in vitro 6. Brain organoids: models of cell type diversity, connectivity, and disease phenotypes Section II: The use of iPSC-derived neurons to study neurological disorders 7. Human models as new tools for drug development and precision medicine 8. Use of cerebral organoids to model environmental and gene x environment interactions in the developing fetus and neurodegenerative disorders 9. iPSC-derived models of autism: Tools for patient phenotyping and assay-based drug discovery 10. Probing the electrophysiological properties of patient-derived neurons across neurodevelopmental disorders 11. Advantages and limitations of hiPSC-derived neurons for the study of neurodegeneration Section III: New technology, industry perspective, and transitioning to the clinic 12. Developing clinically translatable screens using iPSC-derived neural cells 13. Gene editing hPSCs for modeling neurological disorders 14. Cell therapy and biomanufacturing using hiPSC-derived neurons 15. Ethical considerations for the use of stem cell-derived therapies
